Home » Stocks » ARVN

Arvinas, Inc. (ARVN)

Stock Price: $62.54 USD -2.15 (-3.32%)
Updated Apr 19, 2021 2:26 PM EDT - Market open
Market Cap 3.16B
Revenue (ttm) 21.80M
Net Income (ttm) -119.33M
Shares Out 48.46M
EPS (ttm) -3.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $62.54
Previous Close $64.69
Change ($) -2.15
Change (%) -3.32%
Day's Open 64.47
Day's Range 62.02 - 65.95
Day's Volume 157,411
52-Week Range 19.68 - 92.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...

1 week ago - GlobeNewsWire

Investors saw some downwards pressure on the indices to kick off Monday. But Q.ai's deep learning algorithms have crunched the numbers to bring you today's top short plays.

Other stocks mentioned: CVNA, NSTG, PLUG, RDFN
3 weeks ago - Forbes

Bank shares are leading the way in what looks to be a green day. In the meantime, Q.ai's deep learning algorithms have crunched the numbers to bring you today's top shorts.

Other stocks mentioned: PAR, ZVO
3 weeks ago - Forbes

Today marks the one-year anniversary since the start of the bull market. Make the most of it with today's top short plays from Q.ai's deep learning algorithms.

Other stocks mentioned: ALGT, CVNA, NCMI
3 weeks ago - Forbes

NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...

1 month ago - GlobeNewsWire

Bond yields are rising again, crushing tech stocks. But the deep learning algorithms at Q.ai have crunched the data to give you a set of Top Shorts for today.

Other stocks mentioned: CDLX, RDFN, SABR, WKHS
1 month ago - Forbes

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.92% and -70.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Arvinas (NASDAQ:ARVN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 76.79% year over year to ($0.99), which missed the estimate of (...

1 month ago - Benzinga

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

2 months ago - GlobeNewsWire

Arvinas is a leader in protein degrader technology. They have shown first outstanding results in phase 1 trials in breast and prostate cancer.

3 months ago - Seeking Alpha

NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PRO...

3 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: FL, GME, NTAP, BCAB, COUP, EOSE, GWRE ...
3 months ago - Benzinga

NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PRO...

4 months ago - GlobeNewsWire

Arvinas (ARVN) announces promising interim data on its two clinical stage pipeline candidates, ARV-471 and ARV-110, for treating breast cancer and prostate cancer, respectively.

4 months ago - Zacks Investment Research

NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PRO...

4 months ago - GlobeNewsWire

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific upd...

Other stocks mentioned: ANPC, ARPO, SYBX, VERU
4 months ago - Benzinga

Arvinas (ARVN) news for Monday includes positive interim results from clinical trials sending ARVN stock soaring to new highs. The post Arvinas News Alert: Why ARVN Stock Is Skyrocketing Today appeared ...

4 months ago - InvestorPlace

– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated patient...

4 months ago - GlobeNewsWire

– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET –

4 months ago - GlobeNewsWire

NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

4 months ago - GlobeNewsWire

– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial –

5 months ago - GlobeNewsWire

NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

6 months ago - GlobeNewsWire

NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

6 months ago - GlobeNewsWire

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...

7 months ago - GlobeNewsWire

NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...

8 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -12.07% and 0.40%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today ...

8 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

8 months ago - Zacks Investment Research

NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...

9 months ago - GlobeNewsWire

NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...

10 months ago - GlobeNewsWire

NEW HAVEN, Conn., June 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...

10 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

10 months ago - Zacks Investment Research

- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response -

10 months ago - GlobeNewsWire

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe.

Other stocks mentioned: ALLO, AMGN, CTMX, MGNX
11 months ago - Benzinga

Investors were hoping for better initial data from an early-stage trial of its prostate cancer therapy.

11 months ago - The Motley Fool

- Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality -

11 months ago - GlobeNewsWire

Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

11 months ago - Zacks Investment Research

Shares of Arvinas (NASDAQ:ARVN) rose 1.5% after the company reported Q1 results.

11 months ago - Benzinga

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of 5.08% and 20.46%, respectively, for the quarter ended March 2020.

11 months ago - Zacks Investment Research

NEW HAVEN, Conn., April 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today pro...

1 year ago - GlobeNewsWire

NEW HAVEN, Conn., March 31, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...

1 year ago - GlobeNewsWire

Is (ARVN) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -5.66% and 2.69%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Arvinas.

1 year ago - Zacks Investment Research

Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience

1 year ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Other stocks mentioned: DBX, TRN
1 year ago - Benzinga

About ARVN

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastati... [Read more...]

Industry
Biotechnology
IPO Date
Sep 27, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ARVN
Full Company Profile

Financial Performance

In 2020, Arvinas's revenue was $21.80 million, a decrease of -49.27% compared to the previous year's $42.98 million. Losses were -$119.33 million, 69.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for Arvinas stock is "Strong Buy." The 12-month stock price forecast is 109.09, which is an increase of 74.43% from the latest price.

Price Target
$109.09
(74.43% upside)
Analyst Consensus: Strong Buy